Instruments:
The 1 H NMR spectra was characterized by a Bruker Dmx500 MHz spectrometer (Switzerland) at room temperature. The mass spectra (MS) was determined by a Bruker Autoflex-3 smart beam mass spectrometer with MALDI-TOF.
The Micro-morphologies of DBBC-UiO were obtained by a transmission electron microscope (TEM, JEM-2000FX). The X-ray diffraction (XRD) analysis was measured on with a Cu-Kα radiation (λ=0.15418 nm). The UV-vis absorption spectra was acquired by using a JASCO V-570 spectrophotometer (JASCO, Japan), and the Fourier Transform Infrared (FT-IR) spectroscopy was examined in a PerkinElmer spectrum by preparing sample pellets with KBr. The zeta potential and dynamic light scattering (DLS) analysis were performed through a Zetasizer Nano-ZS ZEN3600 Preparation of DBBC-UiO: DBBC-UiO was prepared according to the previous literature. H 2 DBBC (3.5 mg, 0.006 mmol) was dissolved in 1 mL of N,N-dimethylformamide (DMF), and HfCl 4 (2 mg, 0.006 mmol) was dissolved in 1 mL of DMF and 0.15 mL of acetic acid (2.6 mmol). The two above solutions were mixed in a glass vial and kept at 90°C for three days. After cooling down to room temperature, caliper for 15 days and normalized against their initial sizes (0 days). Two days after treatment, the mice from each groups were sacrificed, and the tumors and other major organs (including heart, liver, kidney, spleen and lung) were explanted and collected for anatomy and histo-pathological analysis.
Scheme S1. The main synthesis routes. DBBC-UIO adopts the same structure of Zr 6 O 4 (OH) 4 (Zn-DPDBP) 6 from the PXRD analysis ( Figure S11 ). Meanwhile, the ligand length of DPDBP in the Zr 6 O 4 (OH) 4 (Zn-DPDBP) 6 is similar to the H 2 DBBC in the proposed DBBC-UiO.
Thus, we speculated the single structural unit of DBBC-UiO using Crystal structure software Materials Studio. 
